Potential hypersensitivity due to the food or food additive content of medicinal products in Spain

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 7, 2011, Pages 496-506

  Audicana Berasategui, M T ^a   Barasona Villarejo, M J ^b   Corominas Sanchez M ^c   de Barrio Fernandez M ^d   Garcia Aviles M C ^e   Garcia Robaina J C ^f   Gastaminza Lasarte, G ^g   Lagun Martinez J J ^h   Lobera Labairu, T ⁱ   Lopez San Martin M ^j   Martin Lazaro J ^k   Moreno Rodilla, E ^l   Ortega Rodriguez N ^m   Torres Jaen M J ⁿ  

^a HOSPITAL TXAGORRITXU   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL DE TORREVIEJA   (Spain)

^f HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

ⁱ HOSPITAL SAN PEDRO   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k Universidad de La Coruña   (Spain)

^l HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^m HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

ⁿ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

more..

Author keywords

Additive; Drug allergy; Egg; Food allergy; Milk

Indexed keywords

ANTIGRIPAL PASTEUR; ANTIGRIPAL POLI LETI; ANTIPAROTIDITIS MSD; ANTISARAMPION LLORENTE; BRONCHODILATING AGENT; CHITIN DERIVATIVE; DRUG ADDITIVE; EVAGRIP; EXCIPIENT; FERROUS SULFATE; FISH OIL; FOOD ALLERGEN; GLUCOSAMINE; IMUVAC; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; IRON PROTEIN SUCCINYLATE; LACTIC ACID; LACTOFERRIN; LACTOSE; LISOZIMA CHIESI; LYSOZYME; LYSOZYME CHLORIDE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MILK PROTEIN; MSD TRIPLE; MUMPS VACCINE; OVALBUMIN; PHOSPHATIDYLCHOLINE; POLYLACTIC ACID; PROBIOTIC AGENT; PROPAFENONE; PROPOFOL; PROPOFOL FRESENIUS; PROPOFOL LIPOMED; PROPOFOL MAYNE; RAPAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AROMA; ASTHMA; BRONCHOSPASM; CRUSTACEA; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG PACKAGING; DRUG SAFETY; DYSPNEA; EGG ALLERGY; ERYTHEMA; FOOD ALLERGY; GRANULOMATOUS INFLAMMATION; HUMAN; HYPOTENSION; LARYNX SPASM; LIPOATROPHY; OCCUPATIONAL ASTHMA; PERIORAL ERYTHEMA; PRURITUS; REVIEW; RHINITIS; SHELLFISH; SPAIN; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

DRUG HYPERSENSITIVITY; FOOD ADDITIVES; FOOD HYPERSENSITIVITY; GLUCOSAMINE; HUMANS; LACTOSE; MURAMIDASE; OVALBUMIN; PROPOFOL; SPAIN;

EID: 83755206568     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Real Decreto 1345/2007, de 11 de octubre, transposition ofEuropean Directives 2001/83/CE and 2004/27/CE, por el que se regula el procedimiento de autorización, registro y condiciones de dispensación de los medicamentos de uso humano fabricados industrialmente. BOE 267 de 7/11/2007, sección 1 pag 145652-98.
2. Ley 29 de 26 de julio de 2006 de garantías y uso racional de medicamentos y productos sanitarios.
3. Directive 2004/27/CE of the European Parliament and Council, 31st of March.
4. Circular 2/2008. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ministerio de Sanidad y Consumo. 5 de Marzo de 2008.
5. Real Decreto 1245/2008, de 18 de julio, por el que se modifica la norma general de etiquetado, presentación y publicidad de los alimentos. BOE 184 de 31/7/ 2008, sección 1 pag 32976-78.
6. Muzzarelli RA. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Marine Drugs. 2010;8:292-312.
7. Gray HC, Hutcheson PS, Salvin RG. Is glucosamine safe in patients with seafood allergy? J Allergy Clin Immunol. 2004;114:456-60.
8. Villacis J, Rice R, Bucci LR, El-Dahr JM, Wild L, DeMerell D, Soteres D, Lehrer B. Do shrimp-allergic individuals tolerate 505 MT Audícana Berasategui, et al shrimp-derived glucosamine? Clin Exp Allergy. 2006;36:1457-61.
9. Frémont S, Kanny G, Nicolas JP, Moneret-Vautrin DA. Prevalence of lysozyme sensitization in an egg-allergic population. Allergy. 1997;52:224-8.
10. Artesani MC, Donnanno S, Cavagni G, Calzone L, D'Urbano L. Egg sensitization caused by immediate hypersensitivity reaction to drug-containing lysozyme. Ann Allergy Asthma Immunol. 2008;1:101-5.
11. Ledesma Benitez I, Reguera Santos L, Lapena Lopez de Armentia S. Adverse drug reaction as the form of onset of egg sensitization. An Pediatr (Barc). 2007;66:424-5.
12. Pérez-Calderón R, Gonzalo-Garijo MA, Lamilla-Yerga A, Mangas-Santos R, Moreno-Gastón I. Recurrent angioedema due to lysozyme allergy. J Investig Allergol Clin Immunol. 2007;17:264-6.
13. Pichler WJ, Campi P. Allergy to lysozyme/egg white-containing vaginal suppositories. Ann Allergy. 1992;69:521-5.
14. Kobayashi M, Yamamoto O, Yasuda H Asahi M. A case of toxic epidermal necrolysis-type drug eruption induced by oral lysozyme chloride. J Dermatol. 2000;27:401-4.
15. Fujisawa K, Oshima Y, Mayumi M. An infantile case with eggwhite allergy induced by maternal usage of lysozyme chloride. Allergy in Practice. 2000;258:146-8.
16. Park HS, Nahm DH. New occupational allergen in a pharmaceutical industry: serratial peptidase and lysozyme chloride. Ann Allergy Asthma Immunol. 1997;78:225-9.
17. Santaolalla M, De Barrio M, De Frutos C, Gandolfo M, Zuberdía J, Rubio M. Rodríguez A, Baeza ML. Double sensitization to enzymes in a baker. Allergy. 2002;57:957.
18. Larramendi CH, Marco FM, García Abujeta JL, Mateo M, de la Vega A, Sempere JM. Acute allergic reaction to an iron compound in a milk-allergic patient. Pediatric Allergy Immunol. 2006;17:230-3.
19. Corominas M, Garcia Robaina JC, Rodríguez V, Delgado J, Garcia Ortega P. Reacciones alérgicas inducidas por fármacos poco habituales (II): de masa molecular alta u orgánicos. In: Tratado de Alergología, Tomo II., Pelaez A, Dávila J, Eds. Ergon, Madrid. 2007;1557-84.
20. Verloet D, Pradal M, Birnbaum J, Koeppel MC. Drug Allergy, Eds. Phadia AB, Paris 2008.
21. De Barrio M, Fuentes V, Sánchez I, Zubeldia J, Tornero P, Herrero T. Anaphylaxis to oral iron salts. Desensitization protocol for tolerance induction. J Invest Allergol Clin Immunol. 2008;18:305-8.
22. Food Allergy Comittee of the Sociedad Española de Inmunología Clínica y Alergología Pediátrica (SEICAP). Allergología e Immunología. 2007;35:209-12.
23. Kakoo GA, Lack G. Guidelines for measles vaccination in eggallergic children. Clin Exp Allergy. 200;30:288-93.
24. Cerecedo I, Dieguez MC, Bartolomé B, B, Sánchez Cano M, De la Hoz B. Safety of measles-mumps-rubella vaccine (MMR) in patients allergic to eggs. Allergol Immunopathol (Madr). 2007;35:105-9.
25. Kelso JM, Yunginger JW. Immunization of eggs-allergic individuals with egg- or chicken-derived vaccines. Immunol Allergy Clin North Am. 2003;23:635-48
26. http://www.imedicinas.com/GPTage/Home.php
27. Eda A, Sugai K, Shioya H, Fujitsuka A, Ito S, Iwata T, Funabiki T. Acute allergic reaction due to milk proteins contaminating lactose added to corticosteroid for injection. Allergol Int. 2009;58:137-9. Epub 2009 Jan 25.
28. Nowak-Wegrzyn A, Shapiro GG, Beyer K, Bardina L, Sampson HA. Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J Allergy Clin Immunol. 2004;113:558-60.
29. Tsuruta D, Sowa J, Kobayashi H, Ishii M Fixed food eruption caused by lactose identified after oral administration of four unrelated drugs. J Am Acad Dermatol. 2005;52:370-1.
30. Cox NH, Duffey P, Royle J. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol. 1999;40:263-4.
31. Fiocchi A, Restani P, Leo G, Martelli A, Boyque GR, Terracciano L, Ballabio C, Valsasina R. Clinical tolerance to lactose in children with cow's milk allergy. Pediatrics. 2003;112:359-62.
32. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) en relación con las consecuencias asociadas al consumo de isoflavonas Número de referencia: AESAN-2007-002. Documento aprobado por el Comité Científico en sesión plenaria de 27 de febrero de 2007.
33. Beliveau S, Gaudreault P, Goulet L, Primeau MN, Marcoux D. Type I hypersensitivity in an asthmatic child allergic to peanuts: was soy lecithin to blame? J Cutan Med Surg. 2008;12:27-30.
34. Facchini G, Antonicelli L, Cinti B, Bonifazi F, Massei V. Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. Monaldi Arch Chest Dis. 1996;51:201-3.
35. Andersen HL, Nissen I. [Presumed anaphylactic shock after infusion of Lipofundin]. Ugeskr Laeger. 1993;155:2210-1.
36. Mark BJ, Beaty AD, Slavin RG. Are fish oil supplements safe in finned fish-allergic patients? Allergy Asthma Proc. 2008;29:528-9.
37. Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanacul W, Duggan C, Puder M, Lenders C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005;24:839-47.
38. Lavaud F, Perdu D, Prevost A, Vallerand H, Cossart C, Passemard F. Baker's asthma related to soybean lecithin exposure. Allergy. 1994;49:159-62.
39. Palm M, Moneret-Vautrin DA, Kanny G, Denery-Papini S, Fremont S. Food allergy to egg and soy lecithins. Allergy 1999;54:1116-7.
40. Porras O, Carlsson B, Fallstrom SP, Hanson LA. Detection of soy protein in soy lecithin, margarine and, occasionally, soy oil. Int Arch Allergy Appl Immunol. 1985;78:30-2.
41. Awazuhara H, Kawai H, Baba M, Matsui T, Komiyama A. Antigenicity of the proteins in soy lecithin and soy oil in soybean allergy. Clin Exp Allergy. 1998;28:1559-64.
42. Mark BJ, Beaty AD, Slavin RG. Are fish oil supplements safe in finned fish-allergic patients? Allergy Asthma Proc. 2008;2:528-9.
43. Lizaso Bacaicoa MT, Acero Sáinz S, Álvarez Puebla MJ, Muro Leyún MD, García Figueroa BE, Echechipía Madoz S, Tabar Purroy AI. Respuesta cutánea a Diprivan® (propofol) e Intralipid® en pacientes alérgicos a huevo y leguminosas. Rev Esp Alergol Inmunol Clín. 1998;3:153-7.
44. Base de Datos del Medicamento. Consejo General de Colegios Oficiales de Farmacéuticos, 2010.
45. Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan®). Anaesthesiology. 1992;77:275-80.
46. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10:3639-49.
47. Bassett CW, Talusan-Canlas E, Holtzin L, Kumar S, Chiaramonte LT. Case report: an adverse reaction to propofol in a patient with egg hypersensitivity. J Allergy Clin Immunol. 1994;93:242.
48. Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother. 2003;37:398-401.
49. Fechner J, Ihmsen H, Jeleazcov C, Schüttler J. Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol). Expert Opin Investig Drugs. 2009;18:1565-71.
50. Welliver M, Rugari SM. New drug, fospropofol disodium: a propofol prodrug. AANA Journal. 2009;77(4):301-8.
51. Buchman AL, Ament ME. Comparative hypersensitivity in intravenous lipid emulsions. JPEN J Parenter Enteral Nutr. 1991;15:345-6.
52. Palm MD, Woodhall KE, Butterwick KJ, Goldman MP. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients. Dermatol Surg 2010;36:161-70.
53. Roca B. Adverse drug reactions to antiretroviral medication. Front Biosci. 2009;14:1785-92.
54. Narins RS. Minimizing adverse events associated with poly-Llactic acid injection. Dermatol Surg. 2008;34:S100-4.
55. Andre P, Lowe NJ, Parc A, Clerici TH, Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther. 2005;7:171-6.
56. Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. Lateonset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology. 2009;219:303-8. Epub 2009 Oct 1.
57. Tabar AI, Muro MD, Quirce S, Olaguibel JM. Contact dermatitis due to sensitization to lactic acid and castor oil in a wart remover solution. Contact Dermatitis. 1993;29:49-50.
58. Matheu V, Zapatero L, Alcázar M, Martínez-Molero MI, Baeza ML. IgE-mediated reaction to a banana-flavored drug additive. J Allergy Clin Immunol. 2000;106:1202-3.
59. van Assendelft AH. Bronchospasm induced by vanillin and lactose. Eur J Respir Dis. 1984;65:468-72.
60. Kumar A, Rawlings RD, Beaman DC. The mystery ingredients: sweeteners, flavorings, dyes, and preservatives in analgesic/ antipyretic, antihistamine/decongestant, cough and cold, antidiarrheal, and liquid theophylline preparations. Pediatrics. 1993;91:927-33.
61. Kanny G, Hatahet R, Moneret-Vautrin DA, Kohler C, Bellut A. Allergy and intolerance to flavouring agents in atopic dermatitis in young children. Allerg Immunol (Paris). 1994;26:204-6, 209-10.
62. Fuglsang G, Madsen G, Halken S, Jørgensen S, Ostergaard PA, Osterballe O. Adverse reactions to food additives in children with atopic symptoms. Allergy. 1994;49:31-7.
63. Taylor SL, Dormedy ES. The role of flavoring substances in food allergy and intolerance. Adv Food Nutr Res. 1998;42:1-44.
64. Peroni DG, Dall'Agnola A, Piacentini GL, Boner AL. Worsening of atopic dermatitis by hazelnut essence contained in hydroxyzine syrup. Acta Paediatr. 2007;96:1710. Epub 2007 Sep 19.
65. De Benito V, Alzaga R. Occupational allergic contact dermatitis from cassia (Chinese cinnamon) as a flavouring agent in coffee. Contact Dermatitis. 1999;40:165.
66. Kind F, Scherer K, Bircher AJ. Allergic contact stomatitis to cinnamon in chewing gum mistaken as facial angioedema. Allergy. 2010;65:276-7.
67. Hershko K, Weinberg I, Ingber A. Exploring the mango-poison ivy connection: the riddle of discriminative plant dermatitis. Contact Dermatitis. 2005;52:3-5.